Olympus expands its innovation commitment with USD150M Venture Capital Fund II

JAPAN/USA—Olympus Corporation, a global MedTech leader dedicated to improving health and enhancing quality of life, has announced a renewed commitment to its corporate venture capital initiative with the launch of Olympus Innovation Ventures Fund II.

The new fund, established under Olympus Innovation Ventures, LLC (OIV), marks a significant milestone in the company’s ongoing strategy to accelerate healthcare innovation across core specialties.

Building on the success of its initial corporate venture fund, Olympus will deploy USD 150 million to invest in emerging and promising MedTech startups.

These investments will focus primarily on companies developing breakthrough technologies in Gastrointestinal (GI), Urology, and Respiratory care.

The latest initiative reflects Olympus’ continuing efforts to foster innovation that drives better patient outcomes and strengthens its leadership position within the global MedTech ecosystem.

OIV operates as a wholly owned subsidiary of Olympus Corporation of the Americas and plays a pivotal role in identifying and nurturing strategic opportunities.

The venture arm seeks to generate a steady pipeline of mergers and acquisitions, partnerships, and valuable market intelligence.

While it maintains a stage-agnostic approach, OIV prioritises early- to growth-stage companies worldwide that are advancing therapeutic solutions in Olympus’ targeted medical fields.

Beyond financial investment, Olympus extends active support to its portfolio companies by offering clinical and technical expertise, access to healthcare professionals and hospitals, and a well-established global platform to commercialize and scale innovations.

This approach allows the company to collaborate closely with founders and innovators who are reshaping the delivery of medical care through next-generation technologies.

Since its establishment in October 2021, OIV has made nine strategic investments in key areas such as AI-powered workflow solutions and medical imaging agents for cancer detection, underscoring its focus on technology-driven healthcare transformation.

Bob White, Director, Representative Executive Officer, President, and Chief Executive Officer of Olympus, emphasized that the expanded venture fund demonstrates the company’s deep commitment to continuous innovation and growth.

He noted that by supporting visionary innovators and groundbreaking technologies, Olympus aims to accelerate development of solutions that enhance patient care and bolster its standing within the MedTech industry.

Cerity Partners Ventures (Cerity), a firm known for its expertise in corporate venture capital, will continue to manage the Olympus venture fund in close collaboration with senior executives at Olympus.

According to Kindra Tatarsky, Partner at Cerity Partners Ventures, the team looks forward to strengthening its partnership with Olympus by leveraging collective technical expertise, strong industry networks, and strategic insight.

She highlighted that the new fund will further advance Olympus Innovation Ventures’ mission to become the partner of choice for top healthcare innovators and startups worldwide.

Gabriela Kaynor, Executive Officer and Chief Strategy Officer at Olympus—and Chair of the OIV Investment Committee—shared that this additional commitment to venture capital investment reinforces Olympus’ strategy to support startup teams creating cutting-edge, endoscopy-enabled solutions.

 She added that Olympus Innovation Ventures continues to contribute toward developing the “endosuite of the future,” integrating capabilities for early detection, diagnosis, and advanced therapies powered by AI, robotics, and next-generation technologies.

Through these strategic investments, Olympus continues to expand its reach and strengthen its role as a driving force in medical innovation, partnership development, and technology advancement across the global healthcare landscape.